GlassScriptPhysician profile
Andrew William King
NPI 1932588803
$2,922.27
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $924 · 2021: $512 · 2022: $188 · 2023: $25.11 · 2024: $45.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $588.38 | 2019-2020 | |
| Novo Nordisk INC | $413.88 | 2019-2022 | |
| Amgen INC. | $401.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $206.29 | 2019-2021 | |
| Lilly USA, LLC | $203.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.47 | 2020-2022 | |
| Amarin Pharma, INC. | $114.24 | 2019-2022 | |
| Pfizer INC. | $73.89 | 2019-2022 | |
| Astellas Pharma US INC | $69.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $63.69 | 2019-2020 | |
| Akcea Therapeutics, INC. | $61.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $54.69 | 2019 | |
| Dynavax Technologies Corporation | $45.31 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $41.77 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.89 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2020 | |
| Exact Sciences Corporation | $28.09 | 2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $25.11 | 2023 | Inspire |
| Esperion Therapeutics, INC. | $24.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $23.07 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $17.27 | 2024 | |
| Horizon Therapeutics Plc | $16.73 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.68 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.15 | 2021 | |
| Bausch Health US, LLC | $12.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.